A phase 4, open-label study to evaluate the safety and immunogenicity of DTaP5-HBV-IPV-Hib in children previously vaccinated with DTaP2-HBV-IPV-Hib or DTaP5-HBV-IPV-Hib (V419-016)

Andrea Guerraa Research, MSD (UK) Limited, London, UKView further author information

Claudio Costantinob Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Excellence Specialties, University of Palermo, Palermo, ItalyView further author information

Federico Martinon-Torresc Translational Pediatrics and Infectious Diseases, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain;d GENVIP Research Group (www.genvip.eu), Instituto de Investigación Sanitaria de Santiago, Universidad de Santiago de Compostela, Santiago de Compostela, Spain;e Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, SpainView further author information

Soeren Westerholtf Pediatrics, Praxis für Kinder- und Jugendmedizin, Wolfsburg, GermanyView further author information

Courtney Lambethg Research, Merck & Co., Inc., Rahway, NJ, USAView further author information

Ziqiang Cheng Research, Merck & Co., Inc., Rahway, NJ, USAView further author information

Jessie Lumleyg Research, Merck & Co., Inc., Rahway, NJ, USAView further author information

Tomas Marcekh Vaccine, MCM Vaccine B.V, Leiden, NetherlandsView further author information

David Johnsoni Vaccine, Sanofi Vaccines, Swiftwater, PA, USAView further author information

Marissa Wilckg Research, Merck & Co., Inc., Rahway, NJ, USACorrespondence[email protected]

https://orcid.org/0000-0002-6890-1118 View further author information

(for the V419-016 study group)

show all

A phase 4, open-label study to evaluate the safety and immunogenicity of DTaP5-HBV-IPV-Hib in children previously vaccinated with DTaP2-HBV-IPV-Hib or DTaP5-HBV-IPV-Hib (V419-016)

V419_016_manuscript_Supplement_for_resubmission.docx

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A phase 4, open-label study to evaluate the safety and immunogenicity of DTaP5-HBV-IPV-Hib in children previously vaccinated with DTaP2-HBV-IPV-Hib or DTaP5-HBV-IPV-Hib (V419-016)

V419_016_manuscript_Supplement_for_resubmission.docx

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date